LEARNING OBJECTIVES:

Upon completion of this activity, participants should be able to:

1. Determine patient selection for treatment in HCC.
2. Explain rationale for immunotherapy in HCC.
3. Describe the efficacy and safety data of new combinations in HCC.

Speaker Disclosure:
Dr. Finn has disclosed that he is a consultant for Adaptimmune, AstraZeneca, Bayer, BristolMyers, EliLilly, Eisai, C Stone, Pfizer, Merck, and Roche/Genentech. Dr. Finn has also disclosed that research support has been previously paid to UCLA from: Adaptimmune, Bayer, BristolMyers, EliLilly, Eisai, Pfizer, Merck and Roche/Genentech. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Section # 1673